Daclizumab Versus Rabbit Antithymocyte Globulin in High-Risk Renal Transplants: Five-Year Follow-up of a Randomized Study.

@article{Hellemans2015DaclizumabVR,
  title={Daclizumab Versus Rabbit Antithymocyte Globulin in High-Risk Renal Transplants: Five-Year Follow-up of a Randomized Study.},
  author={Rachel Hellemans and Mark Hazzan and Dominique Durand and Georges Mourad and Philippe Lang and Mich{\`e}le Kessler and Bernard Charpentier and Guy Touchard and Francois Berthoux and Pierre Merville and Nacera Ouali and J P Squifflet and François Bayle and Karl M Wissing and Christian No{\"e}l and Daniel Abramowicz},
  journal={American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons},
  year={2015},
  volume={15 7},
  pages={1923-32}
}
We previously reported a randomized controlled trial in which 227 de novo deceased-donor kidney transplant recipients were randomized to rabbit antithymocyte (rATG, Thymoglobulin) or daclizumab if they were considered to be at high immunological risk, defined as high panel reactive antibodies (PRA), loss of a first kidney graft through rejection within 2 years of transplantation, or third or fourth transplantation. Patients treated with rATG had lower incidences of biopsy-proven acute rejection… CONTINUE READING